Dispelling confusion about de‐prescribing bisphosphonates

John A Eisman and Christopher P White
Med J Aust 2019; 210 (1): . || doi: 10.5694/mja2.12058
Published online: 14 January 2019
Correction(s) for this article: Erratum | Published online: 15 April 2019

Stopping bisphosphonate therapy in people at risk of bone fractures must be carefully considered

The major rationale for starting anti‐resorptive drug treatment in people with osteoporosis is that the risk of further fractures is 2–4 times and that of mortality 2–3 times as great for someone with a fragility fracture as for other people of the same age. This applies to virtually all fractures, and particularly during the 5 years after a fragility fracture.1,2,3

  • John A Eisman1,2
  • Christopher P White3

  • 1 Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, NSW
  • 2 University of Notre Dame Australia, Sydney, NSW
  • 3 Prince of Wales Hospital, Sydney, NSW


Competing interests:

John Eisman has received consulting and research support from Amgen, Eli Lilly, Merck Sharp and Dohme, and Novartis. Christopher White has received consulting and research support from Amgen. None of these companies had any role in the preparation of this Editorial.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.